ArticleJournal of cardiothoracic surgery2026
Practical therapeutic options for postoperative chylothorax.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAn iatrogenic chylothorax following an esophageal or lung resection represents an uncommon complication with a significant morbidity and mortality if not treated promptly. The optimal therapeutic recommendations are not well defined and rely on the results of retrospective clinical series. We reviewed our experience with a consecutive series of patients with major postoperative chylothoraces in addition to published literature to create a rational algorithm for treatment of this frustrating problem.
methodsWe conducted a retrospective cohort study of consecutive esophageal and lung resection patients from July 1, 2004 through June 30, 2021, collecting clinical data on all patients who developed a postoperative chylothorax with careful evaluation of the results of definitive therapy.
resultsBetween July 1, 2004 through June 30, 2021, we reviewed clinical data on 17 esophageal resection patients and 51 lung resection patients over a 17-year interval who underwent definitive treatment for their postoperative chylothorax. The esophageal surgery patients ultimately had curative therapy with total parenteral nutrition (TPN)(18%), medium chain triglyceride (MCT) enteral tube diet (18%), and in performing a surgical ligation of the thoracic duct (35%). For the lung surgery patients, the most effective treatments were octreotide/midodrine(29%), surgical ligation of the thoracic duct (23%) and the performance of a lymphangiogram with embolization or combined with octreotide (15%).
conclusionsAll patients in our cohort of esophageal and lung resection patients had curative therapy of the chylothorax with aggressive, invasive procedures mostly directed toward interruption or ligation of the thoracic duct while some patients responded well to dietary and drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.